eccogene glp 1 Non‐clinical and first‐in‐human characterization of ECC5004/AZD5004, a novel once‐daily, oral small‐molecule GLP‐1 receptor agonist - Haggag - 2025 - Diabetes, Obesity and Metabolism AZD5004

These multitarget drugs are designed to create synergy across pathways that regulate appetite, insulin secretion, hepatic metabolism, and energy expenditure, producing broader metabolic benefits than single-receptor therapies

Protein S-glutathionylation confers cellular resistance to ferroptosis induced by glutathione depletion

P., Kennedy, P

The Acid Reflux Fix Cheat Sheet (Screenshot This) Tip: Start with the free fixes first

How can a laboratory select and use a pathway probe with enough confidence that observed biology is not simply an artifact of concentration drift, stability behavior, solvent mismatch, or assay interference